Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag

Altropus Gmbh

Thomas Putz

Hans Loibner

Gottfried Himmler

Manfred Schuster

Michael Freissmuth

Günter Waxenecker

Markus Klinger

Hesso Farhan

The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian glycosylation.

Immunogenic recombinant antibody

The invention relates to the use of a preparation based on an antibody directed against a tumor-associated glycosylation for preparing a medicament for the prophylactic and/or therapeutic treatment for the reduction or inhibition, respectively, of the growth of tumor cells in a cancer patient, as well as to a pharmaceutical preparation containing an antibody directed against a tumor-associated glycosylation. Moreover, the invention relates to a preparation for pharmaceutical and/or diagnostic use, a diagnostic method and an agent for determining the risk of metastasis formation in a cancer patient, as well as a method of producing a preparation based on a body fluid or tissue, in each case using the antibody directed against a tumor-associated glycosylation.

Use of a preparation based on an antibody directed against a tumor-associated glycosylation

Growing community of inventors

Innsbruck, Austria

Thomas Putz